Latiglutenase for Celiac Disease Shows Symptom, Quality of Life Improvement
ImmunogenX, a clinical stage biotherapeutics company, has published the results of their phase 2 trial testing latiglutenase—an orally administered treatment for celiac disease (CD). Latiglutenase was shown to be safe…
Continue Reading